2. Academic Validation
  3. Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

  • J Med Chem. 2015 Sep 10;58(17):6875-98. doi: 10.1021/acs.jmedchem.5b00680.
Gianluca Papeo 1,  Helena Posteri 1,  Daniela Borghi 1,  Alina A Busel 2,  Francesco Caprera 1,  Elena Casale 1,  Marina Ciomei 1,  Alessandra Cirla 1,  Emiliana Corti 1,  Matteo D'Anello 1,  Marina Fasolini 1,  Barbara Forte 1,  Arturo Galvani 1,  Antonella Isacchi 1,  Alexander Khvat 2,  Mikhail Y Krasavin 2,  Rosita Lupi 1,  Paolo Orsini 1,  Rita Perego 1,  Enrico Pesenti 1,  Daniele Pezzetta 3,  Sonia Rainoldi 1,  Federico Riccardi-Sirtori 1,  Alessandra Scolaro 1,  Francesco Sola 1,  Fabio Zuccotto 1,  Eduard R Felder 1,  Daniele Donati 1,  Alessia Montagnoli 1
Affiliations

Affiliations

  • 1 Oncology, Nerviano Medical Sciences Srl , Viale Pasteur 10, 20014 Nerviano, Milan, Italy.
  • 2 Chemical Diversity Research Institute , Rabochaya St. 2 Khimki, Moscow Region 114401, Russia.
  • 3 Accelera Srl , Viale Pasteur 10, 20014 Nerviano, Milan, Italy.
PMID: 26222319 DOI: 10.1021/acs.jmedchem.5b00680
Abstract

The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-18954
    99.78%, PARP-1抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z